文献速递眼底病与葡萄膜炎

玻璃体腔抗血管内皮生长因子注射与假治疗预防糖尿病视网膜病变视力威胁并发症的随机临床试验

Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2021-01-01

DRCR Retina Network Protocol W 随机临床试验纳入 328 名成人(399 眼)中度至重度非增殖性糖尿病视网膜病变(NPDR)且无中心受累糖尿病黄斑水肿(CI-DME)患眼,比较玻璃体腔阿柏西普注射与假治疗。2 年时阿柏西普组发生 CI-DME 伴视力下降或增殖性糖尿病视网膜病变(PDR)的累积概率为 16.3%,假治疗组为 43.5%,但两组视力变化无显著差异。

要点

  • 阿柏西普组 2 年发生 CI-DME 伴视力下降或 PDR 的累积概率为 16.3%,假治疗组为 43.5%。
  • 预防性阿柏西普注射未较观察后必要时治疗带来视力获益。

核心结论

  • 在中度至重度 NPDR 眼中,定期阿柏西普注射较假治疗降低 2 年内发生 PDR 或视力下降性 CI-DME 的比例。
  • 但 2 年内预防性治疗未较观察后必要时阿柏西普治疗带来视力获益。

研究设计与样本

  • 随机临床试验,纳入 328 名成人(399 眼)中度至重度 NPDR(ETDRS 严重程度 43-53)且无 CI-DME,来自 64 个美国和加拿大中心。
  • 眼随机分配至 2.0 mg 阿柏西普注射组(n=200)或假治疗组(n=199),基线、1、2、4 月及此后每 4 月给药至 2 年。
  • 2 至 4 年间若眼为轻度 NPDR 或更好则暂缓治疗;两组在发生 CI-DME 伴视力下降或高危 PDR 时均给予阿柏西普。
  • 主要结局为至 2020 年 5 月发生 CI-DME 伴视力下降或 PDR,采用意向性分析。

主要发现

  • 2 年发生 CI-DME 伴视力下降或 PDR 的累积概率:阿柏西普组 16.3%,假治疗组 43.5%。
  • 总体风险比为 0.32(97.5%CI 0.21-0.50;P<.001), favoring 阿柏西普组。
  • 2 年发生 PDR 的累积概率:阿柏西普组 13.5%,假治疗组 33.2%。
  • 2 年发生 CI-DME 伴视力下降的累积概率:阿柏西普组 4.1%,假治疗组 14.8%。

关键数值与推荐

  • NPDR 严重程度采用 ETDRS 分级 43-53。
  • CI-DME 伴视力下降定义为 1 次访视视力下降≥10 个字母或连续 2 次访视下降 5-9 个字母。
  • 高危 PDR 为给予阿柏西普的触发条件之一。

临床怎么用

  • 对中度至重度 NPDR 且无 CI-DME 的眼,可考虑定期阿柏西普注射以降低 2 年内 PDR 或视力下降性 CI-DME 的发生风险。
  • 预防性治疗未显示 2 年视力获益,临床决策需权衡注射负担与并发症预防。

局限性

  • 4 年结果尚未报告,长期视力结局需进一步评估。
  • 研究纳入特定严重程度 NPDR 人群,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The role of anti-vascular endothelial growth factor injections for the management of nonproliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME) has not been clearly established. OBJECTIVE: To determine the efficacy of intravitreous aflibercept injections compared with sham treatment in preventing potentially vision-threatening complications in eyes with moderate to severe NPDR. DESIGN, SETTING, AND PARTICIPANTS: Data for this study were collected between January 15, 2016, and May 28, 2020, from the ongoing DRCR Retina Network Protocol W randomized clinical trial, conducted at 64 US and Canadian sites among 328 adults (399 eyes) with moderate to severe NPDR (Early Treatment Diabetic Retinopathy Study severity level, 43-53), without CI-DME. Analyses followed the intent-to-treat principle. INTERVENTIONS: Eyes were randomly assigned to 2.0 mg of aflibercept injections (n = 200) or sham (n = 199) given at baseline; 1, 2, and 4 months; and every 4 months through 2 years. Between 2 and 4 years, treatment was deferred if the eye had mild NPDR or better. Aflibercept was administered in both groups if CI-DME with vision loss (≥10 letters at 1 visit or 5-9 letters at 2 consecutive visits) or high-risk proliferative diabetic retinopathy (PDR) developed. MAIN OUTCOMES AND MEASURES: Development of CI-DME with vision loss or PDR through May 2020, when the last 2-year visit was completed. RESULTS: Among the 328 participants (57.6% men [230 of 399 eyes]; mean [SD] age, 56 [11] years), the 2-year cumulative probability of developing CI-DME with vision loss or PDR was 16.3% with aflibercept vs 43.5% with sham. The overall hazard ratio for either outcome was 0.32 (97.5% CI, 0.21-0.50; P < .001), favoring aflibercept. The 2-year cumulative probability of developing PDR was 13.5% in the aflibercept group vs 33.2% in the sham group, and the 2-year cumulative probability of developing CI-DME with vision loss was 4.1% in the aflibercept group vs 14.8% in the sham group. The mean (SD) change in visual acuity from baseline to 2 years was -0.9 (5.8) letters with aflibercept and -2.0 (6.1) letters with sham (adjusted mean difference, 0.5 letters [97.5% CI, -1.0 to 1.9 letters]; P = .47). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, among eyes with moderate to severe NPDR, the proportion of eyes that developed PDR or vision-reducing CI-DME was lower with periodic aflibercept compared with sham treatment. However, through 2 years, preventive treatment did not confer visual acuity benefit compared with observation plus treatment with aflibercept only after development of PDR or vision-reducing CI-DME. The 4-year results will be important to assess longer-term visual acuity outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02634333.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Maturi RK, Glassman AR, Josic K, et al. Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial. JAMA Ophthalmol. 2021. PMID: 33784735. doi:10.1001/jamaophthalmol.2021.0606

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。